Toll Free: 1-888-928-9744

Lupus Nephritis - Pipeline Review, H1 2015

Published: Apr, 2015 | Pages: 108 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lupus Nephritis - Pipeline Review, H1 2015

Summary 

Global Markets Direct's, 'Lupus Nephritis - Pipeline Review, H1 2015', provides an overview of the Lupus Nephritis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lupus Nephritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lupus Nephritis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Lupus Nephritis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Lupus Nephritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lupus Nephritis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reason To Buy 

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Lupus Nephritis Overview 8 Therapeutics Development 9 Pipeline Products for Lupus Nephritis - Overview 9 Pipeline Products for Lupus Nephritis - Comparative Analysis 10 Lupus Nephritis - Therapeutics under Development by Companies 11 Lupus Nephritis - Therapeutics under Investigation by Universities/Institutes 12 Lupus Nephritis - Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Lupus Nephritis - Products under Development by Companies 16 Lupus Nephritis - Products under Investigation by Universities/Institutes 17 Lupus Nephritis - Companies Involved in Therapeutics Development 18 AbbVie Inc. 18 Azano Pharmaceuticals Inc. 19 Biogen, Inc. 20 Bristol-Myers Squibb Company 21 Deltanoid Pharmaceuticals Inc. 22 F. Hoffmann-La Roche Ltd. 23 FibroStatin SL 24 GlaxoSmithKline plc 25 Invion Limited 26 Kadmon Corporation, LLC 27 Millennium Pharmaceuticals, Inc. 28 Teva Pharmaceutical Industries Limited 29 Zyrnat Biotherapeutics SL 30 Lupus Nephritis - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 abatacept (recombinant) - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 belimumab - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 BIIB-023 - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 DP-001 - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 FSMAB-26 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 INV-103 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 ixazomib citrate - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 KD-025 - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 laquinimod sodium - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 Monoclonal Antibody for Lupus Nephritis - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 P-Dex - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 RO-5461111 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 venetoclax - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 voclosporin - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Y-175L - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 ZY-11 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 Lupus Nephritis - Recent Pipeline Updates 74 Lupus Nephritis - Dormant Projects 98 Lupus Nephritis - Discontinued Products 100 Lupus Nephritis - Product Development Milestones 101 Featured News & Press Releases 101 Mar 30, 2015: Aurinia Highlights Initiation of Its Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers 101 Feb 09, 2015: Aurinia Pharmaceuticals to Initiate an Open Label Clinical Study to Investigate the Impact of Voclosporin on Lupus Nephritis Biomarkers 101 Dec 11, 2014: Kadmon Corporation's KD025 Named a Top Priority Lupus Treatment Candidate by the Alliance for Lupus Research and the Lupus Research Institute 101 Jun 26, 2014: Aurinia Pharmaceuticals Initiates Phase 2b Clinical Trial of Voclosporin to Treat Lupus Nephritis 102 May 05, 2014: Possible Treatment for Kidney Disease in Lupus Studied at UH 102 May 05, 2014: Kadmon Corporation Presents Results of KD025 Preclinical and Clinical Studies at AAI Annual Meeting 104 Feb 07, 2014: Researchers Exploring Treatment For Lupus-Based Kidney Disease 104 Oct 15, 2013: Kadmon Announces Development Plans for Selective ROCK 2 Inhibitor, KD025, in Psoriasis, Lupus Nephritis and NASH 105 Jun 12, 2013: Teva And Active Biotech Report Positive Results From Phase IIa Study Of Laquinimod In Active Lupus Nephritis 106 Appendix 107 Methodology 107 Coverage 107 Secondary Research 107 Primary Research 107 Expert Panel Validation 107 Contact Us 107 Disclaimer 108
List of Tables
Number of Products under Development for Lupus Nephritis, H1 2015 9 Number of Products under Development for Lupus Nephritis - Comparative Analysis, H1 2015 10 Number of Products under Development by Companies, H1 2015 11 Number of Products under Investigation by Universities/Institutes, H1 2015 12 Comparative Analysis by Late Stage Development, H1 2015 13 Comparative Analysis by Clinical Stage Development, H1 2015 14 Comparative Analysis by Early Stage Development, H1 2015 15 Products under Development by Companies, H1 2015 16 Products under Investigation by Universities/Institutes, H1 2015 17 Lupus Nephritis - Pipeline by AbbVie Inc., H1 2015 18 Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H1 2015 19 Lupus Nephritis - Pipeline by Biogen, Inc., H1 2015 20 Lupus Nephritis - Pipeline by Bristol-Myers Squibb Company, H1 2015 21 Lupus Nephritis - Pipeline by Deltanoid Pharmaceuticals Inc., H1 2015 22 Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 23 Lupus Nephritis - Pipeline by FibroStatin SL, H1 2015 24 Lupus Nephritis - Pipeline by GlaxoSmithKline plc, H1 2015 25 Lupus Nephritis - Pipeline by Invion Limited, H1 2015 26 Lupus Nephritis - Pipeline by Kadmon Corporation, LLC, H1 2015 27 Lupus Nephritis - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 28 Lupus Nephritis - Pipeline by Teva Pharmaceutical Industries Limited, H1 2015 29 Lupus Nephritis - Pipeline by Zyrnat Biotherapeutics SL, H1 2015 30 Assessment by Monotherapy Products, H1 2015 31 Number of Products by Stage and Target, H1 2015 33 Number of Products by Stage and Mechanism of Action, H1 2015 35 Number of Products by Stage and Route of Administration, H1 2015 37 Number of Products by Stage and Molecule Type, H1 2015 39 Lupus Nephritis Therapeutics - Recent Pipeline Updates, H1 2015 74 Lupus Nephritis - Dormant Projects, H1 2015 98 Lupus Nephritis - Dormant Projects (Contd..1), H1 2015 99 Lupus Nephritis - Discontinued Products, H1 2015 100



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify